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Abstract
Hyaluronic acid (HA) is a natural and linear polymer composed of repeating disaccharide units of b-1, 3-N-acetyl
glucosamine and b-1, 4-glucuronic acid with a molecular weight up to 6 million Daltons. With excellent
viscoelasticity, high moisture retention capacity, and high biocompatibility, HA finds a wide-range of applications in
medicine, cosmetics, and nutraceuticals.
Traditionally HA was extracted from rooster combs, and now it is mainly produced via streptococcal fermentation.
Recently the production of HA via recombinant systems has received increasing interest due to the avoidance of
potential toxins. This work summarizes the research history and current commercial market of HA, and then deeply
analyzes the current state of microbial production of HA by Streptococcus zooepidemicus and recombinant systems,
and finally discusses the challenges facing microbial HA production and proposes several research outlines to meet
the challenges.
Keywords: Hyaluronic acid, Streptococcus zooepidemicus, Metabolic engineering, Molecular weight
Introduction
Hyaluronic acid (HA) is composed of disaccharide
repeats of D-glucuronic acid (GlcUA) and N-acetylglu-
cosamine (GlcNAc) joined alternately by b-1, 3 and b-1,
4 glycosidic bonds (Figure 1). The molecular weights of
HA from different sources are highly variable, ranging
from 10
4 to10
7 Da. In the human body, HA occurs in
the salt hyaluronate form and is found in high concen-
trations in the skin, umbilical cord, and vitreous humor
[1]. HA is also present in the capsules of certain micro-
bial strains (e.g., strains of streptococci). HA possesses
significant structural, rheological, physiological, and bio-
logical functions. With distinctive moisturising retention
ability and viscoelasticity, coupled with its lack of immu-
nogenicity and toxicity, HA finds various applications in
the cosmetic, biomedical, and food industries [2].
Traditionally HA was extracted from rooster combs,
and now it is mainly produced via microbial fermenta-
tion with lower production costs and less environmental
pollution [3-7]. HA has been successfully produced on
an industrial scale with Streptococcus sp. as the main
producer. Nevertheless, the production of HA from
Streptococcus sp. is facing a growing concern due to the
fact that streptococci are pathogenic [8]. In this back-
ground, the recombinant HA production has attracted
an increasing interest, and Novozymes has produced
HA with recombinant Bacillus subtilis on an industrial
scale [8].
In this review, the research history, current HA mar-
kets, and HA production by Streptococcus zooepidemicus
and recombinant systems were summarized. And then
the challenges facing the microbial HA production were
discussed, and finally several guidelines in the forthcom-
ing research were proposed.
History
In 1934, Karl Meyer and John Palmer described a new
polysaccharide isolated from bovine vitreous humor.
They found that the substance contained an uronic acid
and an aminosugar, and named the polysaccharide “hya-
luronic acid” from hyaloid (vitreous) + uronic acid [9].
The term “hyaluronan” was introduced in 1986 to con-
form to polysaccharide nomenclature. During the 1930s
and 1940s, HA was isolated from many sources such as
the vitreous body, umbilical cord, rooster comb, and
streptococci [10]. The chemical structure of HA was
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any medium, provided the original work is properly cited.essentially solved by Karl Meyer and his associates, who
found that HA consists of disaccharide repeats of D-glu-
curonic acid (GlcUA) and N-acetylglucosamine
(GlcNAc) joined alternatively by b-1, 3 and b-1, 4 glyco-
sidic bonds (Figure 1).
The physico-chemical characterization of HA was
conducted during the 1950s and 1960s. At a concentra-
tion as low as 0.1%, the HA chains were entangled, and
this resulted in an extremely high and shear-dependent
viscosity [11]. These properties enabled HA to regulate
water balance and flow resistance, and also to act as a
lubricant, and to stabilize structures [2].
The original development of HA as a product used in
clinical medicine was entirely due to Endre Balazs, who
developed the first non-inflammatory, highly purified
high molecular weight HA from the umbilical cords and
rooster combs [12]. In the early 1980s, HA was used to
create plastic intraocular lenses for implantation, and it
became a major material in ophthalmic surgery. A vari-
ety of other applications have since been proposed and
developed.
The rooster comb-based extraction process is facing a
growing concern over the use of animal-derived compo-
nents in biomedical and pharmaceutical applications.
Hence, microbial fermentation has emerged as a new
alternative for HA production. The first commercially
fermented HA was produced from Streptococcus zooepi-
demicus, which remains the current common strain in
the industrial production of HA [5,6,13]. Nevertheless,
the presence of bacterial endotoxins in HA from strep-
tococcal fermentation limits the application of HA in
biomedical field [4,8]. Therefore, recombinant HA pro-
duction has emerged as an attractive alternative. Both
Gram-positive and Gram-negative bacteria were used as
hosts, including Bacillus sp. [3,8], Lactococcos lactis [4],
Agrobacterium sp. [14], and Escherichia coli [15].
The applications of HA depend on its molecular
weight, which is an important quality parameter for
charactering commercial HA products. Yet, the fermen-
tation product is a mixture of HAs with different mole-
cular weights. Obtaining HA with a uniform molecular
weight represents a challenge, and much work has been
conducted to elucidate the molecular weight control
mechanism, which is a current research focus in the
field of microbial HA production [16-18].
HA market
The current worldwide market for HA is estimated to
be over $1 billion [2]. With the knee osteoarthritis
patient population increasing by 26 percent from 15
million in 2000 to 19 million in 2010, the demand for
viscosupplements is expected to escalate. In the US, the
first single-injection HA viscosupplementation product,
Synvisc-One, was approved in February 2009, and the
product gained rapid acceptance by patients and physi-
cians because of its convenience [19]. The European HA
viscosupplementation market is shifting toward shorter
treatment regimens, and the convenience of undergoing
the procedure once will attract more patients through
2013. In the Asia Pacific, the HA viscosupplementation
market will be favorably affected by both the aging and
physically active demographics, as well as rising aware-
ness of the treatment’s benefits among physicians and
patients [20].
The global market for dermal fillers is booming, at
approximately 759 million USD during 2009, according
to Medical Insight Inc. Nowadays, there are almost 100
different dermal fillers on the market, and about half of
them are based on HA. American Society for Aesthetic
Plastic Surgery reports that about 23, 000 dermatolo-
gists, plastic surgeons, and cosmetic surgeons in the US
performed more than 11.8 million surgical and non-sur-
gical cosmetic surgery procedures in 2004, generating
$12.5 billion in fees. The dermal filler market is expand-
ing at an annual rate of more than 25% through 2011 in
the US, and 20% throughout the rest of the world,
reaching $1.5 billion in global sales. The launch of Q-
Med’s Restylane, with NASHA technology (non-animal
stabilized HA), has ushered in a new era in dermal
enhancement. This filler addresses many of the issues
with traditional bovine collagen fillers, namely shelf life,
skin testing, and its animal origin.
Microbial production of HA with Streptococcus
zooepidemicus
Microbial HA production on an industrial scale was
firstly achieved in 1980s by Shiseido. The commonly
used strain in HA production is S. zooepidemicus, which
can produce 6~7 g/L HA under the suitable culture
conditions. Figure 2 shows the synthesis pathway of HA
in S. zooepidemicus. However, the following three
Figure 1 Structure of disaccharide repeating unit of HA.
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cus. 1) The broth viscosity reaches as high as 400~500
mPas at 4~5 g/L HA, causing poor mixing and low oxy-
gen mass transfer rate, and thus HA production is
severely limited. 2) There exists a strong competition
between HA synthesis and cell growth for the common
precursors such as UDP-N-acetyl-glucosamine and
UDP-glucuronic acid. 3) Lactic acid is a main by-pro-
duct of HA fermentation, and the accumulation of lactic
acid results in a strong inhibition of cell growth and HA
synthesis. Extensive studies have been conducted to
improve HA production by S. zooepidemicus,a n dt h e
recent advances are summarized below.
1) The biosynthesis pathway of HA in S. zooepidemicus
The sugar backbone of HA is derived from glucose-6-
phosphate and fructose-6-phosphate. The HA synthesis
pathway can be divided into two sets. In the first set of
reactions, glucose-6-phosphate is converted to glucose-
1-phosphate by a-phosphoglucomutase. UDP-glucose
pyrophosphorylase adds UTP to glucose-1-phosphate to
produce UDP-glucose. Finally, oxidation of the primary
alcohol in UDP-glucose by UDP-glucose dehydrogenase
yields the first HA precursor, UDP-glucuronic acid. In
the second set of reactions, glutamine fructose-6-phos-
phate amidotransferase transfers the amido group from
glutamine to fructose-6-phosphate to yield glucosamine-
6-phosphate. Phosphate group rearrangement by phos-
phoglucosamine mutase produces glucosamine-1-phos-
phate. The acetylated form of this compound is
produced in the next step by phosphoglucosamine acet-
yltransferase. Finally N-acetylglucosamine-1-phosphate
pyrophosphorylase activates the intermediate by the
addition of UTP thus yielding the second HA precursor,
UDP-N-acetylglucosamine.
Figure 2 also shows that HA synthesis and cell growth
share precursors such as glucose-1-phosphate, UDP-glu-
cose, and UDP-N-acetylglucosamine. Thus there is a
competition between HA synthesis and cell growth to
consume the same precursors, and a high specific
growth rate is not favorable for HA synthesis [21]. In
addition, it can be seen that the glycolysis and HA
synthesis compete for the carbon flux. Therefore, weak-
ening the glycolytic process and reducing the rate of
biomass formation are effective for the enhancement of
HA titer and molecular weight. For example, HA titer
was improved from 5.0 to 6.5 g/L by reducing the bio-
mass formation rate via an intermittent alkaline stress
strategy, where the cyclical pH switch from 7.0 (optimal
for cell growth) to 8.5 (sub-optimal for cell growth) was
done every 2 h during 6-16 h [7]. Both the cyclical
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Figure 2 The biological synthesis pathway of HA in Streptococcus zooepidemicus.
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Page 3 of 9temperature switch from 37 to 30°C (reducing cell
growth rate) and the addition of pyruvate (weakening
the glycolytic process) can significantly increase the HA
titer [17].
2) Fermentation medium
Streptococci are nutritionally fastidious lactic acid bac-
teria and can not synthesize some amino acids [21].
Supplementing some amino acids such as arginine and
lysine in the medium was favorable for cell growth and
HA production [22]. The chemically defined medium
(CDM) containing some nutritional factors essential to
growth also can be used for the culture of S. zooepide-
micus, with the same HA concentration and specific HA
production rate relative to complex medium [21]. Zhang
et al. developed a serum-free medium with starch as
exclusive carbon source, and HA concentration reached
6.7 g/L [23]. The mineral ions and initial glucose con-
centration also had significant effects on microbial HA
production [24,25]. The absence of glucose resulted in a
mixed acid metabolism independent of the oxygen sup-
ply, while, for the initial glucose concentrations ranging
from 5 to 90 g/L, the homolactic metabolism was preva-
lent [25].
3) Fermentation conditions
Culture conditions (pH, temperature, agitation speed,
aeration rate, shear stress, dissolved oxygen, and bior-
eactor type) significantly influence the microbial HA
production. The pH and temperature for HA produc-
tion by S. zooepidemicus were usually at 7.0 and 37°C,
respectively [26,27]. The microbial HA production by S.
zooepidemicus is a typically viscous process, and thus
mixing performance and oxygen mass transfer rate sig-
nificantly influence HA production. The effects of agita-
tion speed, aeration rate, shear stress, and dissolved
oxygen on microbial HA production have been exten-
sively studied [22,26-32]. Compared with an anaerobic
culture, an aerobic culture gives higher HA titer and
molecular weight [21,26]. For example, Armstrong and
Johns observed a 20% increase in HA titer when S.
zooepidemicus were grown under aerobic conditions
[21]. Johns et al. also reported that the aerated culture
gave higher HA concentration and yield than the
equivalent anaerobic fermentation [26]. The stimulation
effects of aeration on HA production can be explained
by the following: (1) Oxygen may stimulate the HA
synthesis as the aggregation of streptococcal cells
mediated by their HA capsule shielded them from oxy-
g e nm e t a b o l i t e s ;( 2 )D i s s o l v e do x y g e ni nt h em e d i u m
can redirect the carbon flux towards lactic acid to acetic
acid and thus more ATP can be generated (YATP/glucose
is 3 mol/mol with acetate production against 2 mol/mol
with lactate production). The extra ATP generated dur-
ing the formation of acetate is favorable for the attain-
ment of higher HA titer. (3) The aeration can enhance
acetyl-CoA accumulation as such that more acetyl-CoA
can be diverged from the central carbon metabolism to
replenish acetyl-CoA for the synthesis of HA [32]. Yet,
there is a considerable divergence on the impacts of agi-
tation speed and aeration on the microbial HA produc-
tion. It was observed that HA production was not
affected by aeration rate, whereas it decreased with the
increase of agitation speed [27]. Hasegawa et al.
reported that HA production increased with the
increase of aeration rate and agitation speed; neverthe-
less, too high agitation speed would cause cell damage
and led to a drop in HA concentration [33]. The energy
status was improved via the overexpression of NADH
oxidase in S. zooepidemicus, however, little impact on
HA titer was observed [6]. This divergence may be
explained by the recent study, which indicated that
there existed a critical dissolved oxygen level of 5% air
saturation for HA synthesis [30]. That was to say, when
dissolved oxygen level was lower than 5% of air satura-
tion, the increase of aeration rate and agitation speed
was favorable for microbial HA production; and when
dissolved oxygen level was higher than 5% of air satura-
tion, there was little impact of agitation speed and aera-
tion rate on HA production.
4) Fermentation mode
Various fermentation modes, such as batch, repeated
batch, fed-batch, and continuous culture have been used
for HA production [34-41]. Batch culture is the domi-
nant operation mode for HA production. Compared to
batch culture, fed-batch culture can shorten fermenta-
tion time and thus increase HA productivity [39]. The
combination of fed-batch and batch was found to be
effective for HA production, namely, S. zooepidemicus
were cultured in a fed-batch mode with sucrose concen-
tration at 1.0 g/L during 0-8 h and then batch culture
was performed during 8-20 h with an initial sucrose
concentration of 15 g/L. With this two-stage culture
strategy, HA production was increased by 32% com-
pared to the batch culture [38]. Recently, the repeated
batch culture has also been employed for HA produc-
tion, and HA productivity was significantly enhanced
[35,36]. In an operation that seeded 31% cell, the volu-
metric production rate of the repeated batch culture
( 0 . 5 9gH A / ( L · h ) )w a sf o u n dt ob e2 . 5 - f o l do ft h eb a t c h
culture (0.24 g HA/(L· h)).
Compared with batch operation, continuous operation
can extend culture period, reduce the time spent on
reactor turnover, and decrease the polydispersity of
molecular weight [21,34]. HA production in a chemostat
was, however, not easily achieved due to the instability
of the HA-producing phenotype of highly encapsulated
streptococci strains at high dilution rate [34]. The high-
est dilution rate for stable HA production in a chemo-
stat culture was 0.4 h
-1 [34]. Therefore, the industrial
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tivation [2].
5) Key factors influencing HA molecular weight
Molecular weight is an important quality parameter for
a commercial HA product, as it determines the HA’s
rheological properties, affects physiological response,
and defines suitable applications [42,43]. HA with a high
molecular weight (greater than 10 kDa) has good viscoe-
lasticity, moisture retention, and mucoadhesion, – quali-
ties desirable in the areas of ophthalmology,
orthopedics, wound healing, and cosmetics. Whereas,
HA with a relatively low molecular weight (2-3.5 kDa)
or HA oligosaccharides (10-20 sugars in length) have
shown to promote angiogenesis, induce expression of
inflammatory mediators, and inhibit tumor growth [18].
Compared with anaerobic condition, aeration can
increase the molecular weight of HA due to more
energy can be produced under aerobic conditions [42].
Moreover, a high dissolved oxygen level favored a high
molecular weight, while a high shear stress led to a
lower molecular weight [28]. The decrease of HA mole-
cular weight at high shear stress was caused by the reac-
tive oxygen species generated by NADH oxidase. Thus a
combination of high dissolved oxygen level and mild
shear stress may be an effective strategy to enhance HA
molecular weight.
Besides the culture conditions, the balance between
the synthesis rate of HA and the providing rate of pre-
cursor sugars was also important for the molecular
weight. A high ratio of HA synthase gene (HasA)t o
UDP-glucose-6-dehydrogenase gene (HasB) resulted in a
lower HA molecular weight [18]. Altering this ratio
affected the concentration of precursor sugars and ulti-
mately affected the HA size, and it was an effective
approach to control HA molecular weight [18]. Of the
two sugar precursors, UDP-glucuronic acid and UDP-N-
acetylglucosamine, the latter exerted a dominant effect
on molecular weight [18]. An overexpression of the
genes involved in UDP-glucuronic acid biosynthesis
decreased molecular weight; whereas, an overexpression
of the genes involved in UDP-N-acetylglucosamine bio-
synthesis increased molecular weight [16]. Thus, manip-
ulating an appropriate balance of UDP-N-
acetylglucosamine and UDP-glucuronic acid was neces-
sary to obtain HA with high molecular weight. In addi-
tion, the balance of glycolytic rate and HA synthesis rate
was also important for the molecular weight of HA [17].
Microbial production of HA with other production
systems
Recently, the recombinant HA production has emerged
as an attractive alternative that could alleviate safety
concerns stemming from pathogenic S. zooepidemicus
and avian products. Host bacteria, both Gram-positive
and Gram-negative, include Bacillus sp. [3,8], L. lactis
[4], Agrobacterium sp. [14], and E. coli [15,44,45]. An E.
coli strain (JM109) was engineered into an efficient HA
producer by co-expressing the HA synthase from Pas-
teurella multocida and uridine diphosphate (UDP)-glu-
cose dehydrogenase from E. coli K5 strain [45]. The
engineered strain produced 0.5 g/L HA in shaker flask
and 2.0-3.8 g/L HA in a fed-batch culture process in a
1-L bioreactor [45]. L. lactis was engineered by introdu-
cing the HA synthetic machinery from the has operon
of S. zooepidemicus, and it was found that the insertion
of uridine diphosphate-glucose pyrophosphorylase
(hasC) gene in addition to the HA synthase (hasA)a n d
UDP-glucose dehydrogenase (has B) genes can signifi-
cantly increase HA production [46]. The recombinant L.
lactis NZ9000 strain transformed with the plasmid
pSJR3 (co-expressing hasA, hasB,a n dhasC genes) gave
a maximum of 1.8 g/L HA in a 2.4-L batch bioreactor
[46]. The hasA gene from S. zooepidemicus was
expressed in B. subtilis for the production of HA, and it
was found that the production of UDP-glucuronic acid
is limiting in B. subtilis a n dt h a to v e r e x p r e s s i n gt h e
hasA gene along with the endogenous tuaD gene is suf-
ficient for high-level production of HA in B. subtilis [8].
Agrobacterium sp. ATCC 31749 was engineered by co-
expressing HA synthase gene from P. multocida,a l o n g
with a kfiD gene encoding UDP-glucose dehydrogenase
from E. coli K5 strain [14]. Coexpression of these two
heterologous enzymes enables Agrobacterium to pro-
duce 0.3 g/L HA in shaker flask cultivation [14]. Table 1
shows the HA production with different strains under
different culture conditions. Though HA from Bacillus
is commercially available, in general, the recombinant
strains produced a lower HA titer than streptococci did,
and the forthcoming research should focus on the con-
struction of efficient HA producer with metabolic and
genetic tools.
Perspectives: challenges and opportunities
Though great progresses have been achieved on the
microbial production of HA with S. zooepidemicus and
the recombinant production systems, several challenges
remain.
1) The continuous rise in the cost of raw materials
weakens the commercial competiveness of microbial
HA production, and thus it is necessary to find a
cheaper substrate replacement to reduce production
cost. Furthermore, the needs of a sustainable society
point to the conversion of renewable resources such as
agricultural derivatives into valuable bioproducts.
Thus, exploring the feasibility of producing HA with
cheap crude materials or wastes from the other indus-
t r i a lp r o c e s s e si sw o r t hi n v e stigating. Mussel proces-
sing wastewater (MPW) and tuna peptone (TP) from
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Microorganism Culture mode Culture medium Aeration
parameters
HA titer and
molecular
weight
References
S. equi subsp zooepidemicus
(ATCC 35246)
Batch 2.5 L Maltose 20 g/L, CDM 600 rpm
1.3 vvm
[HA]: 2.14 g/L
MW: 2.1 × 10
6 Da
[5]
S. equi subsp zooepidemicus
deficient in b-glucuronidase
Batch 100 mL Glucose 40 g/L, trypton 10 g/L, yeast
extract 2.5 g/L
Anaerobic condition [HA]:0.4430 g/L
MW:2.21 × 10
6Da
[13]
S. equi subsp zooepidemicus
(ATCC 39920)
Batch 3.7 L CDM 400 rpm
1 vvm
[HA]:3.66 g/L
MW: 3.8 × 10
6Da
[17]
S. equi subsp zooepidemicus
(ATCC 35246)
Batch 2 L Glucose 60 g/L, CDM 600 rpm
1 vvm
[HA]:4.2 g/L
MW: 3.2 × 10
6Da
[21]
S. equi subsp zooepidemicus
WSH-24
Batch 7 L Yeast extract 25 g/L, sucrose 70 g/L 200 rpm
0.5 vvm
[HA]:6.7 g/L
MW: n.d.
[22]
S. equi subsp zooepidemicus
NJUST01
Batch 500 ml Starch 50 g/L, glucose 3 g/L,
peptone 5 g/L
220 rpm [HA]:6.7 g/l
MW: n.d.
[23]
S. equi subsp zooepidemicus G1
(mutant of ATCC39920)
Batch + pulse 5
L
Glucose 40 g/L, polypeptone 20 g/L,
yeast extract 10 g/L
10-80% DO [HA]: 3.5 g/L
MW: 2.19 × 10
6Da
[28]
S. equi subsp zooepidemicus
(ATCC 35246)
Batch 2 L Glucose 20 g/L, yeast extract 10 g/L 600 rpm
0.3 vvm
[HA]:2.1 g/L
MW:n.d.
[26]
S. equi subsp zooepidemicus
(ATCC 39920)
Batch 3 L Glucose20 g/L, yeast extract 10 g/L 300 rpm
1 vvm
[HA]:2.3 g/L
MW:n.d.
[30]
S. equi subsp zooepidemicus
WSH-24
Batch 7 L Yeast extract 25 g/L, sucrose 70 g/L Adding oxygen
vector
200 rpm
0.5 vvm
[HA]:6.6 g/L
MW:n.d.
[31]
S. equi subsp zooepidemicus
(ATCC 39920)
Fed-batch 2.5 L glucose 5 g/L, yeast extract 2.5 g/L 20% DO [HA]:3.5 g/L
MW:n.d
[35]
S. equi subsp zooepidemicus
(ATCC 35246)
cC Continuous
culture 2 L
Glucose 15 g/L, yeast extract 10 g/L 200 rpm
0 vvm
[HA]:0.6 g/L
MW:n.d
[34]
S. equi subsp zooepidemicus
(ATCC 39920)
Repeated batch
3L
Glucose2 0 g/L, yeast extract 10 g/L,
tryptone 1.7 g/L, soytone 0.3 g/L
10%DO 0.59 g HA/(L·h)
MW:n.d
[36]
Streptococcus sp. ID9102
(KCTC1139BP)
Batch 75 L Glucose 40 g/L, yeast extract 7.5 g/L,
casein peptone 10 g/L
400 rpm
0.5 vvm
[HA]:6.94 g/L
MW: 5.9 × 10
6Da
[37]
S. equi subsp zooepidemicus
WSH-24
Fed-batch 7 L Yeast extract 25 g/L, sucrose 70 g/L 200 rpm
0.5 vvm
[HA]:6.6 g/L
MW:n.d
[38]
S. equi subsp zooepidemicus
(ATCC 35246)
Batch 2 L Mussel processing wastewater 50 g/L,
tuna peptone 8 g/L
500 rpm
0 vvm
[HA]:2.46 g/L
MW: 2.5 × 10
6Da
[39]
S. equi subsp zooepidemicus
(ATCC 35246)
Nitrogen-limited
fed-batch 3 L
Yeast extract 10 g/L and a
mixture of inorganic salts
600 rpm.
0.05 vvm.
[HA]:2.2 g/L
MW:n.d
[40]
S. equi subsp zooepidemicus
(ATCC 39920)
Batch 2 L Glucose (10-60) g/L, yeast extract 10 g/
L
300 rpm,
1.3 vvm.
[HA]:1.8 g/L
MW:2.52 × 10
6 Da
[41]
S. equi subsp zooepidemicus
(ATCC 39920)
Batch 3 L glucose 25 g/L yeast extract 60 g/L 250 rpm
2 vvm
[HA]:1.21 g/L
MW:4 × 10
7Da
[25]
S. equi subsp zooepidemicus
(ATCC 39920)
Batch 125 mL glucose 25 g/L yeast extract 60 g/L 150 rpm
liquid volume: 50
mL in 125 mL
[HA]:0.65 g/L
MW:7.4 × 10
7Da
[24]
S. equi subsp zooepidemicus
mutant
Fed-batch 100 L CDM 400-1,200 rpm,
0.5-2.0 vvm
[HA]: 6-7 g/L
MW:3.2 × 10
6 Da
[27]
S. equi subsp zooepidemicus
#104
Batch 2 m
3 Peptone20 g/L, yeast extract 10 g/L 30 rpm;
0.5 vvm;
0.05 MPa.
MW:4.3 × 10
6 Da [33]
S. equi subsp zooepidemicus
(ATCC) 39920
Batch 250 mL Agricultural resource derivatives
medium
150 rpm [HA]:0.89 g/L,
MW:10
3 to 10
4 Da
[47]
Recombined Bacillus subtilis
(hasA-hasD-VHb)
Batch 250 mL Modified minimal medium, 10 g/L
glucose
170 rpm
liquid volume: 50
mL in 250 mL flask
[HA]:1.8 g/L
MW:n.d.
[3]
Liu et al. Microbial Cell Factories 2011, 10:99
http://www.microbialcellfactories.com/content/10/1/99
Page 6 of 9viscera residue are used for HA production by S. zooe-
pidemicus, and the economic analysis indicated that
the production cost can be reduced by more than 30%
with the by-products as the culture medium [39]. The
agricultural resource derivatives such as cashew apple
j u i c ew a sap r o m i s i n gm e d i u mf o rt h em i c r o b i a lH A
production [47]. For another example, the large
amount of crude glycerol produced in the biodiesel
industry, if not properly treated, pose a significant
environmental concern. Therefore, we can explore the
potential of microbial HA production with the crude
glycerol as a substrate. Of course, process engineering
for the efficient treatment of crude material and meta-
bolic engineering of microbes for the efficient utiliza-
tion of raw substrates should be considered to achieve
this objective.
2) Whether for S. zooepidemicus or the recombinant
systems like E. coli, B. subtilis, and L. lactis, the key fac-
tors limiting HA synthesis need to be further clarified.
The tools of metabolic engineering, such as metabolic
flux analysis (MFA) and metabolic control analysis
(MCA), can be employed to develop a rational strategy
to improve HA yield and molecular weight. MFA is an
analysis technique used to calculate and analyze the flux
distribution of the entire biochemical reaction network
during a process. MCA quantifies the relation between
genetic modifications or environmental changes and cel-
lular process responses [48]. MCA introduces the con-
trol coefficients to quantify the fractional change of
cellular output, such as metabolite concentrations and
metabolic fluxes, in response to fractional change of
system parameters, such as enzyme activities and growth
conditions [49]. The combination of MFA and MCA
can be used to investigate the metabolic responses of
HA producer to the environmental changes or the
expression of key genes related with HA synthesis. With
the information gathered from MFA and MCA, the
optimal strategies (both process control and key genes
expression) can be determined to improve HA titer and
molecular weight.
3) It is necessary to obtain specially designated mole-
cular weight or uniform size-defined HA to extend the
applications of HA and make better HA containing bio-
medical products. To achieve low polydispersity, we
must know the regulatory mechanisms of initiation and
elongation during the HA polymer synthesis process.
Despite HA polymerization model has been put forward
and some key intracellular metabolites influencing mole-
cular weight have been clarified, much work needs to be
performed to understand the mechanism of molecular
weight control.
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Table 1 Overview of HA titer and molecular weight with different microorganisms under different culture conditions
(Continued)
Recombinant Lactococcus lactis
(hasA-hasB)
Batch 250 mL M17 medium, 10 g/L glucose 170 rpm
liquid volume: 50
mL in 250 mL flask
[HA]:0.65 g/l
MW:n.d.
[2]
Recombinant Bacillus subtilis
RB161(hasA-tuaD-gtaB)
Fed-batch 3 L minimal medium with sucrose 1300 rpm
1.5 vvm
MW:1 × 10
6 Da [8]
Recombinant Escherichia coli
(sshasA-ssugD)
Fed-batch 250
mL
LB medium liquid volume: 40
mL in 250 mL flask
[HA]:190 mg/L
MW:3.5 × 10
5 to
1.9 × 10
6 Da
[15]
Recombinant Agrobacterium sp.
(pmHas-kfiD)
Batch 250 mL LB medium 250 rpm
liquid volume: 50
mL in 250 mL flask
[HA]:0.3 g/L
MW:0.7 × 10
6 to 2
×1 0
6 Da
[14]
Recombinant S. equi subsp
zooepidemicus
(hasA-hasB-hasC-hasD-hasE)
Batch 2 L glucose 20 g/L, uridine 50 mg/L, CDM 300 rpm
0 vvm
MW:1.8 × 10
6 to
3.4 × 10
6 Da
[16]
Recombinant Escherichia coli
(pmHas-kfiD)
Fed-batch 1 L Glucose 45 g/L, GlcNAc 11.8 g/L 10%DO [HA]:3.8 g/L
MW:n.d.
[45]
Recombinant Escherichia coli
(sz-hasA with rare codon
modifications)
Batch LB medium. — [HA]:32.5 mg/L [44]
Recombinant Lactococcus lactis
(hasA-hasB-hasC-hasD-hasE)
Batch 2.4 L M17 medium, 20 g/L glucose 200 rpm
1 vvm
[HA]:1.8 g/L [46]
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